<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer Milan</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3208039</article-id><article-id pub-id-type="publisher-id">396</article-id><article-id pub-id-type="doi">10.1007/s10194-011-0396-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Suggested randomized, controlled trial for frovatriptan: a reply</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Omboni</surname><given-names>Stefano</given-names></name><address><email>info@iitelemed.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pinessi</surname><given-names>Lorenzo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Savi</surname><given-names>Lidia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fierro</surname><given-names>Brigida</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bartolini</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lisotto</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Zanchin</surname><given-names>Giorgio</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label>Italian Institute of Telemedicine, Varese, Italy </aff><aff id="Aff2"><label>2</label>Department of Neurology, University of Torino, Turin, Italy </aff><aff id="Aff3"><label>3</label>Department of Neurology and Psychiatry, University of Palermo, Palermo, Italy </aff><aff id="Aff4"><label>4</label>Department of Neuroscience, Polytechnic University of Marche, Ancona, Italy </aff><aff id="Aff5"><label>5</label>Ospedale Civile San Vito al Tagliamento, San Vito al Tagliamento, Italy </aff><aff id="Aff6"><label>6</label>Department of Neurology, University of Padova, Padua, Italy </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>10</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>10</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2011</year></pub-date><volume>12</volume><issue>6</issue><fpage>663</fpage><lpage>664</lpage><history><date date-type="received"><day>3</day><month>10</month><year>2011</year></date><date date-type="accepted"><day>6</day><month>10</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2011</copyright-statement></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2011</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Dear Sir,</p><p>We read with interest the comments of Dr. Tfelt-Hansen [<xref ref-type="bibr" rid="CR1">1</xref>] regarding our three recently published randomized controlled trials comparing patients&#x02019; preference (primary endpoint) and efficacy (secondary endpoints) of frovatriptan 2.5&#x000a0;mg versus zolmitriptan 2.5&#x000a0;mg [<xref ref-type="bibr" rid="CR2">2</xref>], rizatriptan 10&#x000a0;mg [<xref ref-type="bibr" rid="CR3">3</xref>] and almotriptan 12.5&#x000a0;mg [<xref ref-type="bibr" rid="CR4">4</xref>], and the meta-analysis of pooled individual data from the three studies [<xref ref-type="bibr" rid="CR5">5</xref>]. In all studies frovatriptan showed similar preference and short-term efficacy outcomes (pain relief and pain-free episodes at 2&#x000a0;h) with respect to the other three triptans.</p><p>The questions put by Dr. Tfelt-Hansen sound appropriate. Doubts are raised on the usefulness of head-to-head preference trials of triptans and on the actual translation of their results into the clinical practice. We agree that patients may probably switch over time from one triptan to another because of individual preference, which might not be in line with results of randomized, controlled, comparative studies. However, the availability of results of head-to-head preference and efficacy trials may help physicians to make a first choice which might be very close to the actual patient&#x02019;s preference. We should remind that some evidence on triptan preference in clinical practice does exist, even if we recognize that a tighter link between trials and clinical practice might be developed, for instance, by appropriate surveys [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p>It is true that some guidelines usually refer to simple (and cheaper) oral analgesics and anti-emetics or pro-kinetic as the first line treatment of acute migraine, escalating to a (more expensive) triptan if this approach fails [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. This might sound reasonable in terms of the efficacy, because, as mentioned by Dr. Telft-Hansen, a meta-analysis showed that aspirin and sumatriptan act similarly in migraineurs [<xref ref-type="bibr" rid="CR10">10</xref>]. More recently a publication from the same group showed a good efficacy of aspirin in treatment of acute migraine of moderate or severe intensity [<xref ref-type="bibr" rid="CR11">11</xref>]. However, we think that a comparative study with sumatriptan, namely the oldest among triptans, might not be ideal, because newer triptans have been proved to be more effective than sumatriptan, with differences in the onset time of headache relief according to the characteristics of the studied triptan [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Even though the efficacy of some triptans and aspirin might be similar in the acute phase of migraine, it is undisputable that triptans have a more definite place in treatment of chronic and recurrent migraine attacks in the most published guidelines. In addition, oral analgesics, like aspirin, are not an exempt from adverse events, as shown by a recent meta-analysis [<xref ref-type="bibr" rid="CR14">14</xref>]. At the light of the current evidence we think that choice of use of non-steroidal anti-inflammatory-drugs or triptans for treatment of migraine headache should be based on several considerations, including characteristics of migraine, drug efficacy, patient&#x02019;s preference and drug safety in the individual subject. Unfortunately, only a few of these aspects are taken into account in the current recommendations.</p></body><back><ack><title>Conflict of interest</title><p>All authors have occasionally served as scientific consultants for manufacturers of frovatriptan, zolmitriptan, rizatriptan or almotriptan.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Tfelt-Hansen P, Steiner TJ (2011) Suggested randomized, controlled trial with frovatriptan. J Headache Pain. doi:10.1007/s10194-011-0381-x</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tullo</surname><given-names>V</given-names></name><name><surname>Allais</surname><given-names>G</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name><name><surname>Curone</surname><given-names>M</given-names></name><name><surname>Mea</surname><given-names>E</given-names></name><name><surname>Omboni</surname><given-names>S</given-names></name><name><surname>Benedetto</surname><given-names>C</given-names></name><name><surname>Zava</surname><given-names>D</given-names></name><name><surname>Bussone</surname><given-names>G</given-names></name></person-group><article-title>Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study</article-title><source>Neurol Sci</source><year>2010</year><volume>31</volume><issue>Suppl.1</issue><fpage>S51</fpage><lpage>S54</lpage><pub-id pub-id-type="doi">10.1007/s10072-010-0273-x</pub-id><pub-id pub-id-type="pmid">20464583</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savi</surname><given-names>L</given-names></name><name><surname>Omboni</surname><given-names>S</given-names></name><name><surname>Lisotto</surname><given-names>C</given-names></name><name><surname>Zanchin</surname><given-names>G</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name><name><surname>Zava</surname><given-names>D</given-names></name><etal/></person-group><article-title>A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine</article-title><source>J Headache Pain</source><year>2011</year><volume>12</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1007/s10194-010-0243-y</pub-id><pub-id pub-id-type="pmid">20686810</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartolini</surname><given-names>M</given-names></name><name><surname>Giamberardino</surname><given-names>MA</given-names></name><name><surname>Lisotto</surname><given-names>C</given-names></name><name><surname>Marteletti</surname><given-names>P</given-names></name><name><surname>Moscato</surname><given-names>D</given-names></name><name><surname>Panascia</surname><given-names>B</given-names></name><etal/></person-group><article-title>A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine</article-title><source>J Headache Pain</source><year>2011</year><volume>12</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1007/s10194-011-0325-5</pub-id><pub-id pub-id-type="pmid">21437714</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortelli</surname><given-names>P</given-names></name><name><surname>Allais</surname><given-names>G</given-names></name><name><surname>Tullo</surname><given-names>V</given-names></name><name><surname>Benedetto</surname><given-names>C</given-names></name><name><surname>Zava</surname><given-names>D</given-names></name><name><surname>Omboni</surname><given-names>S</given-names></name><name><surname>Bussone</surname><given-names>G</given-names></name></person-group><article-title>Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies</article-title><source>Neurol Sci</source><year>2011</year><volume>32</volume><issue>Suppl.1</issue><fpage>S95</fpage><lpage>S98</lpage><pub-id pub-id-type="doi">10.1007/s10072-011-0551-2</pub-id><pub-id pub-id-type="pmid">21533722</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Cutrer</surname><given-names>FM</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name><name><surname>Dodick</surname><given-names>DW</given-names></name><name><surname>McCrory</surname><given-names>D</given-names></name><name><surname>Liberman</surname><given-names>JN</given-names></name><name><surname>Williams</surname><given-names>P</given-names></name></person-group><article-title>How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians</article-title><source>Curr Med Res Opin</source><year>2005</year><volume>21</volume><fpage>413</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1185/030079905X36387</pub-id><pub-id pub-id-type="pmid">15811210</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheftell</surname><given-names>FD</given-names></name><name><surname>Feleppa</surname><given-names>M</given-names></name><name><surname>Tepper</surname><given-names>SJ</given-names></name><name><surname>Volcy</surname><given-names>M</given-names></name><name><surname>Rapoport</surname><given-names>AM</given-names></name><name><surname>Bigal</surname><given-names>ME</given-names></name></person-group><article-title>Patterns of use of triptans and reasons for switching them in a tertiary care migraine population</article-title><source>Headache</source><year>2004</year><volume>44</volume><fpage>661</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2004.04124.x</pub-id><pub-id pub-id-type="pmid">15209687</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">World Health Organization (2010) WHO model list of essential 78 medicines, 16th list. WHO, Geneva. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/medicines/79publications/essentialmedicines/Updated_sixteenth_adult_list_80en.pdf">http://www.who.int/medicines/79publications/essentialmedicines/Updated_sixteenth_adult_list_80en.pdf</ext-link></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Guidelines for All Healthcare Professionals in the Diagnosis and Management of Migraine, Tension-Type Headache, Cluster Headache, Medication-Overuse, Headache. 3rd edition (1st revision) (2010). <ext-link ext-link-type="uri" xlink:href="http://217.174.249.183/upload/NS_BASH/2010_BASH_Guidelines.pdf">http://217.174.249.183/upload/NS_BASH/2010_BASH_Guidelines.pdf</ext-link></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lampl</surname><given-names>C</given-names></name><name><surname>Voelker</surname><given-names>M</given-names></name><name><surname>Diener</surname><given-names>HC</given-names></name></person-group><article-title>Efficacy and safety of 1,000&#x000a0;mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms</article-title><source>J Neurol</source><year>2007</year><volume>254</volume><fpage>705</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1007/s00415-007-0547-2</pub-id><pub-id pub-id-type="pmid">17406776</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Lampl C, Voelker M, Steiner TJ (2011) Aspirin is first-line treatment for migraine and episodic tension-type headache regardless of headache intensity. Headache. [Epub ahead of print]</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name><name><surname>Vries</surname><given-names>P</given-names></name><name><surname>Saxena</surname><given-names>PR</given-names></name></person-group><article-title>Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy</article-title><source>Drugs</source><year>2000</year><volume>60</volume><fpage>1259</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.2165/00003495-200060060-00003</pub-id><pub-id pub-id-type="pmid">11152011</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>MD</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Roon</surname><given-names>KI</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name></person-group><article-title>Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials</article-title><source>Cephalalgia</source><year>2002</year><volume>22</volume><fpage>633</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2002.00404.x</pub-id><pub-id pub-id-type="pmid">12383060</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanas</surname><given-names>A</given-names></name><name><surname>McCarthy</surname><given-names>D</given-names></name><name><surname>Voelker</surname><given-names>M</given-names></name><name><surname>Brueckner</surname><given-names>A</given-names></name><name><surname>Senn</surname><given-names>S</given-names></name><name><surname>Baron</surname><given-names>JA</given-names></name></person-group><article-title>Short-term acetylsalicylic Acid (aspirin) use for pain, Fever, or colds&#x02014;gastrointestinal adverse effects: a meta-analysis of randomized clinical trials</article-title><source>Drugs R D</source><year>2011</year><volume>11</volume><fpage>277</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">21902288</pub-id></mixed-citation></ref></ref-list></back></article>